Učitavanje...
Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
Cariprazine, a potent dopamine D(3) and D(2) receptor partial agonist antipsychotic with preferential binding to D(3) receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from...
Spremljeno u:
| Izdano u: | Int Clin Psychopharmacol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Lippincott Williams And Wilkins
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5625952/ https://ncbi.nlm.nih.gov/pubmed/28692485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000187 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|